[Indication and performance of endocrine surgery. The significance of molecular genetic examination].
The molecular genetic changes from certain endocrine tumors are already understood, reflecting as they do the etiology of these sporadic familial disorders. This already has clinical consequences to the treatment of familial endocrine tumors, which often appear in the course of syndromatic disorders. These consequences consist in slight changes to surgical technique, the search for other active and usually endocrinal tumors, and examination of family members for other gene carriers (of disease-specific mutations) and the most suitable prophylactic tumor therapy. In contrast, for sporadic endocrine tumors there exists far less clinically relevant knowledge. Starting with anamnesis and clinical findings of active endocrine tumors, we discuss the current possibilities for molecular genetic determination of disease-specific mutations (germline and tumor DNA) and their effect on surgical procedure.
Goretzki
P E
PE
Chirurgische Klinik 1, Städtisches Lukaskrankenhaus Neuss und Insulinoma und GEP-Tumor Center Neuss-Düsseldorf, Preussenstrasse 84, Neuss, Germany. pgoretzki@lukasneuss.de
Wirowski
D
D
Schwarz
K
K
Pohl
P
P
Böhner
H
H
Starke
A
A
Lammers
B J
BJ
D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics; D004701:Endocrine Gland Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery*; D006580:Genetic Carrier Screening; D005820:Genetic Testing; D018095:Germ-Line Mutation; D006801:Humans; D010166:Palliative Care; D011379:Prognosis; D013577:Syndrome
D004273:DNA, Neoplasm